Increased copy-number and not DNA hypomethylation causes overexpression of the candidate proto-oncogene CYP24A1 in colorectal cancer

International Journal of Cancer

Volumn 133, Issue 6, 2013, Pages 1380-1388

  Höbaus, Julia ^a   Hummel, Doris M ^a   Thiem, Ursula ^a   Fetahu, Irfete S ^a   Aggarwal, Abhishek ^a   Müllauer, Leonhard ^a   Heller, Gerwin ^a   Egger, Gerda ^a   Mesteri, Ildiko ^a   Baumgartner Parzer, Sabina ^a   Kallay, Enikö ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

20q13.2; colorectal cancer; CYP24A1; methylation; proliferation

Indexed keywords

CALCITRIOL; MESSENGER RNA; RETINOID X RECEPTOR; VITAMIN D RECEPTOR;

ARTICLE; CDC6 GENE; CELL PROLIFERATION; CHROMOSOME 20; COLORECTAL CANCER; CONTROLLED STUDY; CYP24A1 GENE; DNA METHYLATION; DOWN REGULATION; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; GENE FUNCTION; GENE LOCATION; GENE LOCUS; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MCM2 GENE; MCM4 GENE; MCM7 GENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTO ONCOGENE; UPREGULATION;

20Q13.2; COLORECTAL CANCER; CYP24A1; METHYLATION; PROLIFERATION;

ADULT; AGED; CALCIFEDIOL; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DNA METHYLATION; FEMALE; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENES; RNA, MESSENGER; STEROID HYDROXYLASES;

EID: 84879954055     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28143     Document Type: Article

References (50)

1. Giovannucci E,. Epidemiology of vitamin D and colorectal cancer. Anticancer Agents Med Chem 2013; 13: 11-9.
2. Lazzeroni M, Serrano D, Pilz S, et al. Vitamin D supplementation and cancer: review of randomized controlled trials. Anticancer Agents Med Chem 2013; 13: 118-25.
3. Deeb KK, Trump DL, Johnson CS,. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 2007; 7: 684-700.
4. Jones G, Strugnell SA, DeLuca HF,. Current understanding of the molecular actions of vitamin D. Physiol Rev 1998; 78: 1193-231.
5. Dusso AS, Brown AJ, Slatopolsky E,. Vitamin D. Am J Physiol Renal Physiol 2005; 289: F8-F28.
6. Zehnder D, Bland R, Williams MC, et al. Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. J Clin Endocrinol Metab 2001; 86: 888-94.
7. González-Sancho JM, Larriba MJ, Ordõñez-Morán P, et al. Effects of 1alpha,25-dihydroxyvitamin D3 in human colon cancer cells. Anticancer Res 2006; 26: 2669-81.
8. Welsh J,. Cellular and molecular effects of vitamin D on carcinogenesis. Arch Biochem Biophys 2012; 523: 107-14.
9. Horváth HC, Lakatos P, Kõsa JP, et al. The candidate oncogene CYP24A1: A potential biomarker for colorectal tumorigenesis. J Histochem Cytochem 2010; 58: 277-85.
10. Anderson MG, Nakane M, Ruan X, et al. Expression of VDR and CYP24A1 mRNA in human tumors. Cancer Chemother Pharmacol 2006; 57: 234-40.
11. Parise RA, Egorin MJ, Kanterewicz B, et al. CYP24, the enzyme that catabolizes the antiproliferative agent vitamin D, is increased in lung cancer. Int J Cancer 2006; 119: 1819-28.
12. Albertson DG, Ylstra B, Segraves R, et al. Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat Genet 2000; 25: 144-6.
13. Komagata S, Nakajima M, Takagi S, et al. Human CYP24 catalyzing the inactivation of calcitriol is post-transcriptionally regulated by miR-125b. Mol Pharmacol 2009; 76: 702-9.
14. King AN, Beer DG, Christensen PJ, et al. The vitamin D/CYP24A1 story in cancer. Anticancer Agents Med Chem 2010; 10: 213-24.
15. Kent WJ, Sugnet CW, Furey TS, et al. The human genome browser at UCSC. Genome Res 2002; 12: 996-1006.
16. Wang Y, Leung FC,. An evaluation of new criteria for CpG islands in the human genome as gene markers. Bioinformatics 2004; 20: 1170-7.
17. Sharma S, Kelly TK, Jones PA,. Epigenetics in cancer. Carcinogenesis 2010; 31: 27-36.
18. Tashiro K, Ishii C, Ryoji M,. Role of distal upstream sequence in vitamin D-induced expression of human CYP24 gene. Biochem Biophys Res Commun 2007; 358: 259-65.
19. Meyer MB, Goetsch PD, Pike JW,. A downstream intergenic cluster of regulatory enhancers contributes to the induction of CYP24A1 expression by 1alpha,25-dihydroxyvitamin D3. J Biol Chem 2010; 285: 15599-610.
20. Novakovic B, Sibson M, Ng HK, et al. Placenta-specific methylation of the vitamin D 24-hydroxylase gene: implications for feedback autoregulation of active vitamin D levels at the fetomaternal interface. J Biol Chem 2009; 284: 14838-48.
21. Luo W, Karpf AR, Deeb KK, et al. Epigenetic regulation of vitamin D 24-hydroxylase/CYP24A1 in human prostate cancer. Cancer Res 2010; 70: 5953-62.
22. Khorchide M, Lechner D, Cross HS,. Epigenetic regulation of vitamin D hydroxylase expression and activity in normal and malignant human prostate cells. J Steroid Biochem Mol Biol 2005; 93: 167-72.
23. Deeb KK, Luo W, Karpf AR, et al. Differential vitamin D 24-hydroxylase/CYP24A1 gene promoter methylation in endothelium from benign and malignant human prostate. Epigenetics 2011; 6: 994-1000.
24. Ohyama Y, Kusada T, Yamasaki T, et al. Extensive methylation of CpG island of CYP24 gene in osteoblastic ROS17/2.8 cells. Nucleic Acids Res Suppl 2002: 249-50.
25. Marik R, Fackler M, Gabrielson E, et al. DNA methylation-related vitamin D receptor insensitivity in breast cancer. Cancer Biol Ther 2010; 10: 44-53.
26. Shi H, Yan PS, Chen CM, et al. Expressed CpG island sequence tag microarray for dual screening of DNA hypermethylation and gene silencing in cancer cells. Cancer Res 2002; 62: 3214-20.
27. Luo W, Hershberger PA, Trump DL, et al. 24-Hydroxylase in cancer: impact on vitamin D-based anticancer therapeutics. J Steroid Biochem Mol Biol, in press.
28. Meijer GA, Hermsen MA, Baak JP, et al. Progression from colorectal adenoma to carcinoma is associated with non-random chromosomal gains as detected by comparative genomic hybridisation. J Clin Pathol 1998; 51: 901-9.
29. Sillars-Hardebol AH, Carvalho B, Tijssen M, et al. TPX2 and AURKA promote 20q amplicon-driven colorectal adenoma to carcinoma progression. Gut 2011; 61: 1568-75.
30. Fukushige S, Waldman FM, Kimura M, et al. Frequent gain of copy number on the long arm of chromosome 20 in human pancreatic adenocarcinoma. Genes Chromosomes Cancer 1997; 19: 161-9.
31. Lassmann S, Weis R, Makowiec F, et al. Array CGH identifies distinct DNA copy number profiles of oncogenes and tumor suppressor genes in chromosomal- and microsatellite-unstable sporadic colorectal carcinomas. J Mol Med (Berl) 2007; 85: 293-304.
32. Postma C, Hermsen MA, Coffa J, et al. Chromosomal instability in flat adenomas and carcinomas of the colon. J Pathol 2005; 205: 514-21.
33. Hidaka S, Yasutake T, Takeshita H, et al. Differences in 20q13.2 copy number between colorectal cancers with and without liver metastasis. Clin Cancer Res 2000; 6: 2712-7.
34. Ponchel F, Toomes C, Bransfield K, et al. Real-time PCR based on SYBR-Green I fluorescence: an alternative to the TaqMan assay for a relative quantification of gene rearrangements, gene amplifications and micro gene deletions. BMC Biotechnol 2003; 3: 18.
35. Mathieu V, Pirker C, Schmidt WM, et al. Aggressiveness of human melanoma xenograft models is promoted by aneuploidy-driven gene expression deregulation. Oncotarget 2012; 3: 399-413.
36. Pirker C, Lötsch D, Spiegl-Kreinecker S, et al. Response of experimental malignant melanoma models to the pan-Aurora kinase inhibitor VE-465. Exp Dermatol 2010; 19: 1040-7.
37. Wiesner T, Streubel B, Huber D, et al. Genetic aberrations in primary cutaneous large B-cell lymphoma: a fluorescence in situ hybridization study of 25 cases. Am J Surg Pathol 2005; 29: 666-73.
38. Bock C, Reither S, Mikeska T, et al. BiQ Analyzer: visualization and quality control for DNA methylation data from bisulfite sequencing. Bioinformatics 2005; 21: 4067-8.
39. Muhamad P, Chaijaroenkul W, Congpuong K, et al. SYBR Green I and TaqMan quantitative real-time polymerase chain reaction methods for the determination of amplification of Plasmodium falciparum multidrug resistance-1 gene (pfmdr1). J Parasitol 2011; 97: 939-42.
40. Bareis P, Bises G, Bischof MG, et al. 25-hydroxy-vitamin d metabolism in human colon cancer cells during tumor progression. Biochem Biophys Res Commun 2001; 285: 1012-7.
41. Townsend K, Banwell CM, Guy M, et al. Autocrine metabolism of vitamin D in normal and malignant breast tissue. Clin Cancer Res 2005; 11: 3579-86.
42. Friedrich M, Rafi L, Mitschele T, et al. Analysis of the vitamin D system in cervical carcinomas, breast cancer and ovarian cancer. Recent Results Cancer Res 2003; 164: 239-46.
43. Chen G, Kim SH, King AN, et al. CYP24A1 is an independent prognostic marker of survival in patients with lung adenocarcinoma. Clin Cancer Res 2011; 17: 817-26.
44. Hobaus J, Thiem U, Hummel DM, et al. Role of calcium, vitamin d, and the extrarenal vitamin d hydroxylases in carcinogenesis. Anticancer Agents Med Chem 2013; 13: 20-35.
45. Höbaus J, Fetahu IS, Khorchide M, et al. Epigenetic regulation of the 1,25-dihydroxyvitamin D(3) 24-hydroxylase (CYP24A1) in colon cancer cells. J Steroid Biochem Mol Biol 2012.
46. Edelstein PS, Thompson SM, Davies RJ., Altered intracellular calcium regulation in human colorectal cancers and in "normal" adjacent mucosa. Cancer Res 1991; 51: 4492-4.
47. Pretlow TP, Barrow BJ, Ashton WS, et al. Aberrant crypts: putative preneoplastic foci in human colonic mucosa. Cancer Res 1991; 51: 1564-7.
48. Yang C, Wen Y, Li H, et al. Overexpression of minichromosome maintenance 2 predicts poor prognosis in patients with gastric cancer. Oncol Rep 2012; 27: 135-42.
49. Giaginis C, Georgiadou M, Dimakopoulou K, et al. Clinical significance of MCM-2 and MCM-5 expression in colon cancer: association with clinicopathological parameters and tumor proliferative capacity. Dig Dis Sci 2009; 54: 282-91.
50. Lechner D, Manhardt T, Bajna E, et al. A 24-phenylsulfone analog of vitamin D inhibits 1alpha,25-dihydroxyvitamin D(3) degradation in vitamin D metabolism-competent cells. J Pharmacol Exp Ther 2007; 320: 1119-26. Mineral Research